Printer Friendly

Relevance of chronic lyme disease to family medicine as a complex multidimensional chronic disease construct: a systematic review.

1. Introduction

Lyme disease is a worldwide-distributed multisystem animal-borne disease, caused by Borrelia burgdorferi (Bb) sensu lato (Gram-negative Spirochaetes) which is a group of at least 12 closely related species [1]. Recent evidence shows that human cases of Lyme disease may also be caused by more than one species of B. burgdorferi sensu lato [2], with rodents and small mammals as its animal reservoir [3]. Traditionally Lyme disease is divided into four stages, and clinical manifestations may be both cutaneous and systemic and can have cardiovascular, neurological, and musculoskeletal involvement [46]. When Lyme disease is treated with appropriate antibiotic therapy in the early stages, long-term outcomes are good [7].

Lyme disease is the most common vector-borne disease in the USA and Europe with more than 300,000 new cases in the USA [8] and 100.000 cases annually in Europe (estimated from available national data) [9]. However, this number is largely underestimated as case reporting is highly inconsistent and many infections go undiagnosed [10-13]. Global climate change expanding the range of tick vectors and an increase in the incidence suggest that this disease will remain an important health issue in the forthcoming decades [14].

1.1. Definition of Chronic Lyme Disease (CLD). Chronic Lyme disease (CLD) is considered a constellation of persistent symptoms in patients with or without evidence of Bb infection [15, 16]. Some authors use the term CLD only for patients who had been clinically diagnosed with Lyme disease and have persisting symptoms lasting more than 6 months following antibiotic treatment [8]. For this reason the term "posttreatment Lyme disease" [17,18] or "post-Lyme disease syndrome" [10, 18] is often used. The category of "probable Lyme disease" was recently added to the CDC surveillance case definition to describe patients with serologic evidence of exposure and physician-diagnosed disease in the absence of objective signs [19]. Recently, the term chronic arthropodborne neuropathy (CAN) has been proposed as an alternative to chronic Lyme disease, as calling the chronic illness "Lyme disease" causes confusion to patients and physicians [20].

1.2. Evidence on Persistent Bb Infection. There is growing and well-documented evidence to the concept of persistent Bb infection in both animals [21-31] and humans [32-41]. Recent evidence shows Bb is able to escape from destruction by the host immune reactions, persist in host tissues, and sustain chronic infection and inflammation, despite aggressive antibiotic challenge [32, 35, 36, 42-44]. An estimated 20% of patients display recurrent symptoms after antibiotic treatment [45]. A recent study showed that, at six months following antibiotic treatment, 36% of patients reported new-onset fatigue, 20% widespread pain, and 45% neurocognitive difficulties without evidence of depressive symptomatology [46]. Some studies have provided evidence on pleocytosis and the production of Bb antibodies in the cerebrospinal fluid of patients with neuroborreliosis [47], while this is contradicted by other studies showing greater variability in such patients [48]. When looking at the clinical and basic science research, it is apparent that persistent Bb infection and associated inflammation and molecular mimicry mechanisms are associated with gradually increasing encephalopathy and gradually increasing mental symptoms [49]. Despite available evidence, both treatment-refractory infection and persistent symptoms that are related to Bb infection remain subject to controversy in which national medical societies, patient advocacy groups, insurance companies, lawyers, doctors, the private health medical sector, and scientific journals all have become embroiled [10, 50-53]. The controversy is exacerbated by the lack of a clinical or microbiologic definition and the frequent occurrence of chronic symptoms in the general population [54]. The Lyme disease controversy can also be largely linked to the misconception that neurobehavioral effects of illness constitute evidence of nervous system infection. Appropriate differentiation between neuroborreliosis (nervous system Borrelia burgdorferi infection) and Lyme encephalopathy (altered nervous system function in individuals with systemic but not nervous system infection)--or encephalopathies of other etiologies--would lessen the controversy considerably, as the attribution of nonspecific symptoms to supposed ongoing central nervous system infection is a major factor perpetuating the debate [17].

1.3. CLD as a Poorly Understood Chronic Disease Construct. Because of the absence of solid evidence on prevalence [20], causes [55], diagnostic criteria and treatment options [56], the role of autoimmunity to residual or persisting antigens, and the role of a toxin or other bacterial-associated products that are responsible for the symptoms and signs [57], CLD remains a relatively poorly understood chronic disease construct. The role and performance of family medicine in the detection, integrative treatment, and follow-up of CLD are not well studied either. The purpose of this paper is to describe the complexity of CLD as a multidimensional chronic disease construct and its relevance to family medicine by means of a systematic literature review. This paper is a second paper in a series on chronic diseases [58] that focus on complex chronic conditions.

2. Methods

A systematic review method was used to document the complexity and multidimensionality of CLD. In addressing the objective of this review, we used a parallel search strategy via Medline, The Cochrane Library of Systematic Reviews, CINAHL (Cumulative Index to Nursing and Allied Health Literature), and PRE-CINAHL, complemented with a reference review of key articles. Articles had to be published between October 2009 and October 2014.

Articles were selected if they dealt with (1) CLD care complexity; (2) CLD case (patient) complexity; (3) the complexity of CLD quality assessment; and (4) complexity of CLD at the health system level. In addition the studies had to produce insights into the complexity of CLD with relevance to family medicine. Nonsystematic reviews, opinions, and grey literature were excluded from the search. The search strategy included a combination of Medical Subject Headings (MeSH) terms with regard to Lyme disease. We also scrutinised extra sources for further identification of studies by hand-searching the reference lists of all articles. By focusing on CLD care, case, quality assessment, and health systems complexity, we further build on four major and interrelated components of complexity in chronic care that have been described by Borgermans et al. [59]. Each of these components represents a range of elements that contribute to the picture of complexity in chronic care.

Two authors carried out independent screening of titles and abstracts using the specific inclusion and exclusion criterion reported on previously. We ordered the full text of all citations that met the eligibility criteria or appeared relevant or where relevance/eligibility was not clear from the abstract. In the final screening, two authors independently scrutinised the full texts of studies and recorded the reasons when articles were excluded resolving disagreements by discussion and when necessary referred to a third author. A tool-based assessment of the methodological quality of the studies was not part of this review.

The flow diagram (Figure 1) shows our study selection process and the number of studies included.

3. Results

A total of 967 studies were identified. Finally 945 articles were included for assessment. 72 studies provided insights on CLD care complexity, 9 studies provided insights on CLD case complexity, 2 studies provided insights on CLD quality complexity, and 6 studies provided insights on CLD health system complexity with relevance to family medicine.

3.1. Care Complexity

3.1.1. Diagnosis. It is current practice for physicians to base themselves primarily on clinical signs and symptoms when CLD is suspected. Patients often cannot recall being bitten by a tick or if erythema migrans has occurred. Erythema migrans is pathognomonic and does not require any further laboratory investigations [60], but a careful analysis is recommended as a variety of unconventional histopathologic patterns may occur [61]. In the case of no erythema migrans clinical manifestations are complemented by laboratory tests, including enzyme-linked immunosorbent assay (ELISA) and Western blot testing [62]. Although this two-tier testing is standard practice in both the United States and Europe, the test kits generally differ [63].

There is consistent evidence that the two-tier testing lacks sensitivity, cannot distinguish between current and past infection, cannot be used as a marker for treatment, is often dependent on subjectively scored immunoblots, and is considered expensive [64, 65]. Moreover, the diagnosis of CLD based on clinical manifestations, serological findings, and detection of infectious agents often contradict each other [56, 66, 67]. For this reason a growing number of studies support two-tier testing followed by a sensitive and reliable DNA sequencing for confirmation to support the diagnosis of CLD [68, 69]. Other authors suggest the use of a single tier hybrid antigen immuno-PCR and detection of IgG antibodies only [64]. For cases with a high clinical suspicion of disease, the C6 peptide enzyme immunoassay (EIA) is put forward as a stand-alone test or in the second tier of a 2-tiered algorithm [70]. This assay is based on a peptide (C6), whose amino acid sequence reproduces a conserved, immunodominant region of a single protein of Borrelia burgdorferi. Overall, the use of PCR-based methods appears to be of importance because of the high sensitivity and specificity of these assays [71-73]. However, PCR positivity in the absence of culture positivity following antibiotic treatment should be interpreted with caution since B. burgdorferi DNA and mRNA can be detected in samples long after spirochetes are no longer viable as assessed by classic microbiological parameters [74].

Another novel method including culturing spirochetes from the serum of patients uses a two-step preenrichment process, followed by immunostaining with or without polymerase chain reaction (PCR) analysis [75]. In patients who complied with the strict CDC surveillance case definition for Lyme disease the procedure resulted in positive cultures in 47% at 6 days and 94% at week 16. The Centers for Disease Control and Prevention has however raised concerns about false-positive results caused by laboratory contamination and the potential for misdiagnosis [76]. Some authors put forward the measurement of activity of two lysosomal exoglycosidases, [alpha]-fucosidase (FUC) and [beta]-galactosidase (GAL), in the serum as potential markers of LD [77].

Recent evidence has shown that the presence or absence of chronic Lyme borreliosis may be objectively adjudicated by tissue examinations which demonstrate or which fail to show pathogenic microbes in patients who have received a full course of antibiotics [78]. The use of SPECT scans of the brain using Tc and standard nuclear imaging techniques is considered an objective measure of abnormalities present in patients with otherwise difficult to objectify clinical findings [79]. Brain SPECT scans are abnormal in most patients with chronic Lyme disease, and these scans can be used to provide objective evidence in support of the clinical diagnosis [79].

Overall, studies highlight the need for standardization in diagnostic (serological) testing, as well as the need for studies that discriminate between active disease and past infection.

3.1.2. Differential Diagnosis. A factor that complicates the diagnosis of CLD is that it does not present with isolated subjective symptoms [47]. In undiagnosed patients or posttreatment, Bb may mimic the symptoms and signs of other diseases disorders [80, 81] and for this reason is called "the illness with a thousand faces" Patients present themselves with a wide variety of (often unrelated) clinical manifestations [82]. These symptoms may include fatigue [83], insomnia [49], widespread pain [19], arthritis [84], chronic eye lid edema [85], cataract [86], dermatitis [87], cognitive complaints [19], bilateral hearing loss [88], adult respiratory distress syndrome [89], palpitations, tachycardia [90], syncope [87], tremors, epileptic crises [91], depression, anxiety, panic attacks, catatonia, and psychosis [92], amongst others [93, 94]. Lyme disease might become misdiagnosed as fibromyalgia [95], chronic fatigue syndrome [96, 97], amyotrophic lateral sclerosis [80], autism spectrum disorder [98], Parkinson's disease, rheumatoid arthritis [99], multiple chemical sensitivity, Guillain-Barre syndrome (GBS) [80], and dementia [100], as well as other numerous neurological [101, 102] and psychiatric disorders [88, 103]. Caution is however warranted as misdiagnosis of CLD may result in unnecessary antibiotic courses [104].

Overall, studies show the need for a careful differential diagnosis in patients with suspected CLD and persistent complaints.

3.1.3. Diagnosis of Coinfections. The diagnosis of CLD is even more complex when tick-borne coinfections occur in association with Lyme disease [105], which is the rule rather than the exception [106]. Routine laboratory tests exhibit varying reported sensitivity and are usually unhelpful in diagnosis, as serology fails in terms of specificity and/or sensitivity [107]. Clinically relevant coinfections include Bartonella species [105], Babesia [108], Anaplasma [109], Rickettsia [110], Yersinia enterocolitica, Chlamydophila pneumoniae, Chlamydia trachomatis, Mycoplasma pneumoniae [105], and tick-borne encephalitis virus, amongst others [108, 111]. A particular condition that gets growing attention in patients with CLD is Morgellons disease. Morgellons disease is an emerging skin disease characterized by formation of dermal filaments associated with multisystemic symptoms [112]. Recent studies show that Bb spirochetes were detected in the dermatological specimens from study patients, providing evidence that Morgellons disease is associated with an infectious process [112-115].

Overall, studies highlight the importance of coinfections since they can complicate the diagnostic process and their pathological synergism can exacerbate CLD or induce similar disease manifestations.

3.1.4. Treatment. Treatment options are complicated since the population of individuals reporting CLD are heterogeneous with guidelines contradicting each other. Recommendations about the type and duration of treatments in patients with CLD have no factual basis [57], although prolonged courses of antibiotics are likely to be helpful [52]. Recent biostatistical review reveals that retreatment has meaningful clinical benefit in patients who had prior antibiotic treatment [116, 117], with the use of longer (parenteral) antibiotic therapy often to be justified [118]. Doxycycline is often the preferred agent for oral treatment because of its activity against other tick-borne illnesses, but recent evidence shows that doxycycline-treatment only does not always lead to clinical improvements in either the persistent symptoms or quality of life in patients with CLD [55]. This finding can potentially be explained since single antibiotic use often fails to address the different morphological forms of Bb as well as biofilm formations in patients with CLD. Studies indicate the need to include cell wall and cystic and intracellular drugs in any treatment as the different morphological forms of Bb display differences in sensitivity to antibiotic treatment [119]. As coinfections are present in most patients, the use of specific antibiotics is required. Tetracyclines and macrolides are often used, with quinolones for alternative treatment, particularly gemifloxacin. For Bartonella henselae, Chlamydia trachomatis, and Chlamydophila pneumoniae the combination with rifampicin is recommended [105].

Recent evidence shows that novel therapeutic targets for the treatment of the disease should acknowledge a central role of the neutrophil-activating protein A (NapA) of Bb in promoting both regulatory T-cell response and immune suppression in the cerebrospinal fluid of patients with chronic Lyme borreliosis [120].

Overall, studies show that various therapeutic regimens are used in patients with CLD reflecting the need for individualized approaches.

3.2. Case Complexity. The vector model of complexity (VMC) [121] is a useful model to describe case complexity in patients with CLD. The vector model proposes that the complexity of an individual patient arises out of interactions between different domains: biology, genetics, socioeconomics, environment, behaviour, culture, and the health system. In a chronic condition such as CLD, these "forces" are not easily discerned.

3.2.1. Biology/Genetics. Complexity in CLD along the biology/genetics axis is important since gender distribution in patients with Lyme borreliosis has recently been demonstrated. Patients with cutaneous manifestations of Lyme borreliosis tend to be predominantly female, whereas those with noncutaneous manifestations are predominantly male [122].

3.2.2. Socioeconomics/Environment. Complexity in CLD is introduced along the environment axis with a growing number of studies to document the important relationship between the increase in outdoor activities in wooded areas and the incidence of Lyme disease [123]. Special environmental risk factors include the presence of deer ticks in the home environment, ground cover containing moist humus, and leaf litter in the yard. Distribution areas as well as host and vector ranges of Lyme borreliosis agents turned out to be much wider than previously thought [2,124]. Another element from the environment that contributes to the complexity of CLD is that the variety of Bb genospecies leads to distinction in clinical manifestations of Lyme borreliosis (LB) [125,126]. At present, the risk of exposure to multiple pathogens from a single tick bite and the sources of coinfected ticks are not well understood [108].

3.2.3. Behavior. Complexity in CLD is also introduced along the behavioral axis as CLD has considerable implications on daily life. Patients report a significant and severe decline in health status associated with chronic Lyme disease [15]. The psychological factors in the prediction of Lyme disease course have been poorly studied. Studies have shown that a history of severe, long-term, premorbid, and psychological stress is associated with increased incidence of chronic physical symptoms in Lyme disease patients. Traumatic psychological experiences predating onset of Lyme disease symptoms may play an important etiologic role in the chronicity of these symptoms [127]. As a consequence, the burden of CLD is likely to be underestimated as a consequence of the inadequate recognition of the connection between mental and physical health.

3.3. Quality Assessment Complexity. The complexity of quality assessment is reflected by the lack of tools at the present time that can assess the quality of care delivered to patients with CLD. A limited number of quality indicators at the structure, process, or outcome level of care for patients with CLD exist [8], which is in part a consequence of the lack of research on (the construct of) CLD. In addition, publications that describe approaches to patient involvement in quality indicator development are scarce [128] and to our knowledge nonexisting for patients with CLD.

3.4. Health System Complexity. Health system complexity is of relevance to health seeking behaviour of patient swith CLD. There is an abundance of studies on health seeking behaviour highlighting the importance of health system characteristics and their influence on an individual's behaviour at a given time and place [129, 130]. These influences include the financing of care, access to care, coordination mechanisms, and existing stigma on unexplained medical conditions and values and norms. A large survey conducted in the USA in patients with CLD demonstrated extensive delays in obtaining an initial diagnosis and having poor access to healthcare [46,131]. Patients with CLD are often unsatisfied with care in conventional settings [15]. Negative experiences are associated with reports of dismissive, patronizing, and condescending attitudes in health care providers. Studies show that consultations with complementary and alternative medicine (CAM) practitioners and use of CAM therapies are common [132], representing a cost to patients to be exorbitant and prohibitive.

3.4.1. Relevance of CLD as a Multidimensional Chronic Disease Construct to Family Medicine. We have outlined the importance of case, care, quality assessment, and health system complexity in patients with CLD. The majority of studies focus on CLD care and case complexity with a minority of studies to report on CLD quality assessment and health system complexity.

While specialists are an essential element of the total health care continuum, the majority of patients with CLD will continue to access the health care system through family physicians [133], with hospitalization due to Lyme disease to be rare [134]. But there may be discrepancies in disease awareness among family physicians [135]. A range of persistent misconceptions in family medicine exists, ranging from the reliability of available diagnostic tools, the signs and symptoms of nervous system involvement, the importance of coinfections, the appropriate choice and duration of antimicrobial therapy, the importance of Jarisch-Herxheimer reaction after the commencement of treatment with antibiotics, the curability of the infection, and the cause of symptoms that may persist in some patients after treatment [136-138]. Lyme literate family physicians seem to be rare which provides argument to the diagnosis and treatment of CLD within the context of a broad-based, multidisciplinary approach to determining the best approach [139]. Our analysis on complexity in CLD highlights the importance of comprehensiveness in this disorder. Comprehensiveness is the ability of the family physician to address a broad range of patient problems, whether or not the conditions are within the traditional domain of the specialty in which the physician is trained. Referral to Lyme literate specialists is essential both to meet the patient's needs and to establish an integrated care network where responsibilities and tasks are shared. An effective response to the health needs of those with CLD will especially require family physicians and specialists to expand their collaborative efforts and knowledge of each other's practices and treatments. Collaboration between family physicians, dieticians, and physiotherapists is considered important since healthy lifestyles are essential in the recovery of patients with CLD [140].

Another component of the care responsibility of family physicians is ensuring that patients receive preventive interventions. Prevention of mortality and morbidity may depend on correct early diagnosis and treatment [141]. Family physicians can contribute to public health interventions in high-incidence age groups focusing on accurately communicating risk, improving knowledge both of Lyme disease symptoms and of ticks that carry the disease, as well as teaching preventive behaviors to help reducing tick-borne illness rates [142]. Research has shown that patients' knowledge of tick-borne illnesses is poor [143] and the frequency of practicing preventive behaviors is low [142]. It must be noted, however, that a growing number of patients consult medical sources on the Internet with the aim of increasing their health literacy on the subject. Family physicians must encourage and support their patients in search of reliable sources of information.

4. Conclusion

The controversy on CLD needs to be solved because of the heavy burden of illness associated with CLD in patients with or without evidence of Bb infection. There is a need for the development and establishment of new clinical diagnostic tools with increased accuracy, sensitivity, and specificity, as well as novel treatment approaches that may reduce the burden of illness and concomitant costs posed by CLD. Family physicians have a crucial role to play in the prevention and treatment of the disease fostering an integrative multidisciplinary approach to care.

http://dx.doi.org/10.1155/2014/138016

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] M. Krupka, K. Zachova, E. Weigl, and M. Raska, "Prevention of lyme disease: promising research or sisyphean task?" Archivum Immunologiae et Therapiae Experimentalis, vol. 59, no. 4, pp. 261-275, 2011.

[2] K. L. Clark, B. F. Leydet, and C. Threlkeld, "Geographical and genospecies distribution of borrelia burgdorferi sensu lato DNA detected in humans in the USA," Journal of Medical Microbiology, vol. 63, no. 5, pp. 674-684, 2014.

[3] A. Lewandowska, Z. Kruba, and R. Filip, "Epidemiology of Lyme disease among workers of forest inspectorates in Poland," Annals of Agricultural and Environmental Medicine, vol. 20, no. 2, pp. 329-331, 2013.

[4] G. Biesiada, J. Czepiel, M. R. Lesniak, A. Garlicki, and T. Mach, "Lyme disease: review," Archives of Medical Science, vol. 8, no. 6, pp. 978-982, 2012.

[5] J. Coburn, J. Leong, and G. Chaconas, "Illuminating the roles of the Borrelia burgdorferi adhesins," Trends in Microbiology, vol. 21, no. 8, pp. 372-379, 2013.

[6] C. A. Brissette, E. D. Kees, M. M. Burke, R. A. Gaultney, A. M. Floden, and J. A. Watt, "The multifaceted responses of primary human astrocytes and brain microvascular endothelial cells to the Lyme disease spirochete, Borrelia burgdorferi," ASN neuro, vol. 5, no. 3, pp. 221-229, 2013.

[7] T. M. Jares, M. A. Mathiason, and T. J. Kowalski, "Functional outcomes in patients with Borrelia burgdorferi reinfection," Ticks and Tick-Borne Diseases, vol. 5, no. 1, pp. 58-62, 2014.

[8] L. Johnson, S. Wilcox, J. Mankoff, and R. B. Stricker, "Severity of chronic lyme disease compared to other chronic conditions: a quality of life survey," Peer J, vol. 2, article e322, 2014.

[9] World Health Organization, Regional Office for Europe, E. Lindgren, and T. Jaenson, Lyme Borreliosis in Europe: Influences and Climate Change, Epidemiology, Ecology and Adpatation Measures, World Health Organization, Regional Office for Europe, 2006.

[10] S. W. Dubrey, A. Bhatia, S. Woodham, and W. Rakowicz, "Lyme disease in the United Kingdom," Postgraduate Medical Journal, vol. 90, no. 1059, pp. 33-42, 2014.

[11] C. Perronne, "Lyme and associated tick-borne diseases: global challenges in the context of a public health threat," Frontiers in Cellular and Infection Microbiology, vol. 4, p. 74, 2014.

[12] P. Stefanoff, H. Orlikova, V Prikazsky, C. Bene, and M. Rosinska, "Cross-border surveillance differences: tick-borne encephalitis and lyme borreliosis in the Czech Republic and Poland, 1999-2008," Central European Journal of Public Health, vol. 22, no. 1, pp. 54-59, 1999.

[13] K. Vanthomme, N. Bossuyt, N. Boffin, and V. van Casteren, "Incidence and management of presumption of Lyme borreliosis in Belgium: recent data from the sentinel network of general practitioners," European Journal of Clinical Microbiology and Infectious Diseases, vol. 31, no. 9, pp. 2385-2390, 2012.

[14] D. Radzisauskiene, A. Ambrozaitis, and E. Marciuskiene, "Delayed diagnosis of lyme neuroborreliosis presenting with abducens neuropathy without intrathecal synthesis of Borrelia antibodies," Medicina, vol. 49, no. 2, pp. 89-94, 2013.

[15] A. Ali, L. Vitulano, R. Lee, T. R. Weiss, and E. R. Colson, "Experiences of patients identifying with chronic Lyme disease in the healthcare system: a qualitative study," BMC Family Practice, vol. 15, no. 1, article 79, 2014.

[16] J. R. Palmieri, S. King, M. Case, and A. Santo, "Lyme disease: case report of persistent Lyme disease from Pulaski County, Virginia," International Medical Case Reports Journal, vol. 6, no. I, pp. 99-105, 2013.

[17] J. J. Halperin, "Lyme disease: neurology, neurobiology, and behavior," Clinical Infectious Diseases, vol. 58, no. 9, pp. 1267-1272, 2014.

[18] J. N. Aucott, L. A. Crowder, and K. B. Kortte, "Development of a foundation for a case definition of post-treatment Lyme disease syndrome," International Journal of Infectious Diseases, vol. 17, no. 6, pp. e443-e449, 2013.

[19] J. N. Aucott, A. Seifter, and A. W. Rebman, "Probable late lyme disease: a variant manifestation of untreated Borrelia burgdorferi infection," BMC Infectious Diseases, vol. 12, article 173, 2012.

[20] M. S. Dryden, K. Saeed, S. Ogborn, and P. Swales, "Lyme borreliosis in southern United Kingdom and a case for a new syndrome, chronic arthropod-borne neuropathy," Epidemiology and Infection, 2014.

[21] M. E. Embers, S. W. Barthold, J. T. Borda et al., "Persistence of borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection," PLoS ONE, vol. 7, no. 1, Article ID e29914, 2012.

[22] H. Yrjanainen, J. Hytonen, P. Hartiala, J. Oksi, and M. K. Viljanen, "Persistence of borrelial DNA in the joints of Borrelia burgdorferi-infected mice after ceftriaxone treatment," APMIS, vol. 118, no. 9, pp. 665-673, 2010.

[23] R. K. Straubinger, B. A. Summers, Y.-F. Chang, and M. J. G. Appel, "Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment," Journal of Clinical Microbiology, vol. 35, no. 1, pp. 111-116, 1997

[24] E. Baum, F. Hue, and A. G. Barbour, "Experimental infections of the reservoir species Peromyscus leucopus with diverse strains of Borrelia burgdorferi, a Lyme disease agent," mBio, vol. 3, no. 6, 2012.

[25] V. Preac Mursic, E. Patsouris, B. Wilske, S. Reinhardt, B. Gross, and P. Mehraein, "Persistence of Borrelia burgdorferi and histopathological alterations in experimentally infected animals. A comparison with histopathological findings in human Lyme disease," Infection, vol. 18, no. 6, pp. 332-341, 1990.

[26] P. S. Hefty, C. S. Brooks, A. M. Jett et al., "OspE-related, OspF-related, and Elp lipoproteins are immunogenic in baboons experimentally infected with Borrelia burgdorferi and in human lyme disease patients," Journal of Clinical Microbiology, vol. 40, no. 11, pp. 4256-4265, 2002.

[27] E. Hodzic, D. Imai, S. Feng, and S. W. Barthold, "Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice," PLoS ONE, vol. 9, no. 1, Article ID e86907, 2014.

[28] S. W. Barthold, E. Hodzic, D. M. Imai, S. Feng, X. Yang, and B. J. Luft, "Ineffectiveness of tigecycline against persistent Borrelia burgdorferi," Antimicrobial Agents and Chemotherapy, vol. 54, no. 2, pp. 643-651, 2010.

[29] L. K. Bockenstedt, D. G. Gonzalez, A. M. Haberman, and A. A. Belperron, "Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy," The Journal of Clinical Investigation, vol. 122, no. 7, pp. 2652-2660, 2012.

[30] E. Hodzic, S. Feng, K. Holden, K. J. Freet, and S. W. Barthold, "Persistence of Borrelia burgdorferi following antibiotic treatment in mice," Antimicrobial Agents and Chemotherapy, vol. 52, no. 5, pp. 1728-1736, 2008.

[31] H. Yrjanainen, J. Hytonen, X.-Y. R. Song, J. Oksi, K. Hartiala, and M. K. Viljanen, "Anti-tumor necrosis factor-[alpha] treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice," Journal of Infectious Diseases, vol. 195, no. 10, pp. 1489-1496, 2007.

[32] R. B. Strieker and L. Johnson, "Borrelia burgdorferi aggrecanase activity: more evidence for persistent infection in Lyme disease," Frontiers in Cellular and Infection Microbiology, vol. 3, p. 40, 2013.

[33] K. Hansen, C. Crone, and W. Kristoferitsch, "Lyme neuroborreliosis," Handbook of Clinical Neurology, vol. 115, pp. 559-575, 2013.

[34] R. B. Stricker and L. Johnson, "Chronic lyme disease: liberation from lyme denialism," The American Journal of Medicine, vol. 126, no. 8, pp. e13-e14, 2013.

[35] K. Berndtson, "Review of evidence for immune evasion and persistent infection in Lyme disease," International Journal of General Medicine, vol. 6, pp. 291-306, 2013.

[36] E. Jacek, B. A. Fallon, A. Chandra, M. K. Crow, G. P Wormser, and A. Alaedini, "Increased IFN[alpha] activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits," Journal of Neuroimmunology, vol. 255, no. 1-2, pp. 85-91, 2013.

[37] X. Li, G. A. McHugh, N. Damle, V. K. Sikand, L. Glickstein, and A. C. Steere, "Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or lyme arthritis," Arthritis and Rheumatism, vol. 63, no. 8, pp. 2238-2247, 2011.

[38] D. F Battafarano, J. A. Combs, R. J. Enzenauer, and J. E. Fitzpatrick, "Chronic septic arthritis caused by Borrelia burgdorferi" Clinical Orthopaedics and Related Research, no. 297, pp. 238-241, 1993.

[39] J. Oksi, M. Marjamaki, J. Nikoskelainen, and M. K. Viljanen, "Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis," Annals of Medicine, vol. 31, no. 3, pp. 225-232, 1999.

[40] D. Picha, L. Moravcova, D. Holeckova et al., "Examination of specific DNA by PCR in patients with different forms of Lyme borreliosis," International Journal of Dermatology, vol. 47, no. 10, pp. 1004-1010, 2008.

[41] S. Priem, G. R. Burmester, T. Kamradt, K. Wolbart, M. G. Rittig, and A. Krause, "Detection of Borrelia burgdorferi by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting lyme arthritis after antibiotic therapy," Annals of the Rheumatic Diseases, vol. 57, no. 2, pp. 118-121,1998.

[42] J. Miklossy, "Chronic or late lyme neuroborreliosis: analysis of evidence compared to chronic or late neurosyphilis," The Open Neurology Journal, vol. 6, pp. 146-157, 2012.

[43] J. Miklossy, S. Donta, K. Mueller, O. Nolte, and G. Perry, "Chronic or late lyme neuroborreliosis: present and future," The Open Neurology Journal, vol. 6, p. 78, 2012.

[44] A. Bhattacharjee, J. S. Oeemig, R. Kolodziejczyk et al., "Structural basis for complement evasion by lyme disease pathogen Borrelia burgdorferi," The Journal of Biological Chemistry, vol. 288, no. 26, pp. 18685-18695, 2013.

[45] C.-Y. Huang, Y.-W. Chen, T.-H. Kao et al., "Hyperbaric oxygen therapy as an effective adjunctive treatment for chronic Lyme disease," Journal of the Chinese Medical Association, vol. 77, no. 5, pp. 269-271, 2014.

[46] J. N. Aucott, A. W. Rebman, L. A. Crowder, and K. B. Kortte, "Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here?" Quality of Life Research, vol. 22, no. 1, pp. 75-84, 2013.

[47] U. Ljostad and A. Mygland, "Chronic Lyme; diagnostic and therapeutic challenges," Acta Neurologica Scandinavica, vol. 127, no. 196, pp. 38-47, 2013.

[48] M. Vrethem, M. Widhe, J. Ernerudh, U. Garpmo, and P Forsberg, "Clinical, diagnostic and immunological characteristics of patients with possible neuroborreliosis without intrathecal Ig-synthesis against borrelia antigen in the cerebrospinal fluid," Neurology International, vol. 3, no. 1, 2011.

[49] R. C. Bransfield, "The psychoimmunology of lyme/tick-borne diseases and its association with neuropsychiatric symptoms," The Open Neurology Journal, vol. 6, pp. 88-93, 2012.

[50] C. Sordet, "Chronic lyme disease: fact or fiction?" Joint Bone Spine, vol. 81, no. 2, pp. 110-111, 2014.

[51] P M. Lantos, P G. Auwaerter, and G. P Wormser, "A systematic review of borrelia burgdorferi morphologic variants does not support a role in chronic lyme disease," Clinical Infectious Diseases, vol. 58, no. 5, pp. 663-671, 2014.

[52] M. S. Klempner, P J. Baker, E. D. Shapiro et al., "Treatment trials for post-Lyme disease symptoms revisited," The American Journal of Medicine, vol. 126, no. 8, pp. 665-669, 2013.

[53] P G. Auwaerter and M. T. Melia, "Bullying Borrelia: when the culture of science is under attack," Transactions of the American Clinical and Climatological Association, vol. 123, pp. 79-8990, 2012.

[54] P M. Lantos, "Chronic Lyme disease: the controversies and the science," Expert Review of Anti-Infective Therapy, vol. 9, no. 7, pp. 787-797, 2011.

[55] J. Sjowall, A. Ledel, J. Ernerudh, C. Ekerfelt, and P. Forsberg, "Doxycycline-mediated effects on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a randomized, prospective, cross-over study," BMC Infectious Diseases, vol. 12, article 186, 2012.

[56] A. W. Rebman, L. A. Crowder, A. Kirkpatrick, and J. N. Aucott, "Characteristics of seroconversion and implications for diagnosis of post-treatment Lyme disease syndrome: acute and convalescent serology among a prospective cohort of early Lyme disease patients," Clinical Rheumatology, 2014.

[57] S. T. Donta, "Issues in the diagnosis and treatment of lyme disease," The Open Neurology Journal, vol. 6, pp. 140-145, 2012.

[58] L. Borgermans, B. Vrijhoef, J. Vandevoorde, J. De Maeseneer, J. Vansintejan, and D. Devroey, "Relevance of hypersexual disorder to family medicine and primary care as a complex multidimensional chronic disease construct," International Journal of Family Medicine, vol. 2013, Article ID 519265, 5 pages, 2013.

[59] L. Borgermans, J. de Maeseneer, H. Wollersheim, B. Vrijhoef, and D. Devroey, "A theoretical lens for revealing the complexity of chronic care," Perspectives in Biology and Medicine, vol. 56, no. 2, pp. 289-299, 2013.

[60] H. I. Huppertz, P Bartmann, U. Heininger et al., "Rational diagnostic strategies for Lyme borreliosis in children and adolescents: recommendations by the committee for infectious diseases and vaccinations of the german academy for pediatrics and adolescent health," European Journal of Pediatrics, vol. 171, no. 11, pp. 1619-1624, 2012.

[61] T. C. Wilson, A. Legler, K. C. Madison, J. A. Fairley, and B. L. Swick, "Erythema migrans: a spectrum of histopathologic changes," The American Journal of Dermatopathology, vol. 34, no. 8, pp. 834-837, 2012.

[62] C. L. Coulon and D. Landin, "Lyme disease as an underlying cause of supraspinatus tendinopathy in an overhead athlete," Physical Therapy, vol. 92, no. 5, pp. 740-747, 2012.

[63] G. P. Wormser, A. T. Tang, N. R. Schimmoeller et al., "Utility of serodiagnostics designed for use in the United States for detection of Lyme borreliosis acquired in Europe and vice versa," Medical Microbiology and Immunology, vol. 203, no. 1, pp. 65-71, 2014.

[64] M. D. Halpern, C. R. Molins, M. Schriefer, and M. W. Jewett, "Simple objective detection of human Lyme disease infection using immuno-PCR and a single recombinant hybrid antigen," Clinical and Vaccine Immunology, vol. 21, no. 8, pp. 1094-1105, 2014.

[65] M. Elamin, T. Monaghan, G. Mulllins et al., "The clinical spectrum of lyme neuroborreliosis," Irish Medical Journal, vol. 103, no. 2, pp. 46-49, 2010.

[66] K. Chan, S. A. Marras, and N. Parveen, "Sensitive multiplex PCR assay to differentiate Lyme spirochetes and emerging pathogens Anaplasma phagocytophilum and Babesia microti," BMC Microbiology, vol. 13, article 295, 2013.

[67] Y. Hansmann, C. Leyer, N. Lefebvre et al., "Feedback on difficulties raised by the interpretation of serological tests for the diagnosis of Lyme disease," Medecine et Maladies Infectieuses, vol. 44, no. 5, pp. 199-205, 2014.

[68] S. H. Lee, J. S. Vigliotti, V. S. Vigliotti, W. Jones, and D. M. Shearer, "Detection of Borreliae in archived sera from patients with clinically suspect Lyme disease," International Journal of Molecular Sciences, vol. 15, no. 3, pp. 4284-4298, 2014.

[69] K. L. Clark, B. Leydet, and S. Hartman, "Lyme borreliosis in human patients in Florida and Georgia, USA," International Journal of Medical Sciences, vol. 10, no. 7, pp. 915-931, 2013.

[70] S. Mavin, E. J. Watson, and R. Evans, "Laboratory diagnosis of Lyme borreliosis in Scottish patients: a novel approach," British Journal of Biomedical Science, vol. 71, no. 2, pp. 51-54, 2014.

[71] A. A. Noda, I. Rodriguez, B. Mondeja, and C. Fernandez, "Design, optimization and evaluation of a polymerase chain reaction for detection of Borrelia spp," Advances in Clinical and Experimental Medicine, vol. 22, no. 5, pp. 639-653, 2013.

[72] M. O'Rourke, A. Traweger, L. Lusa et al., "Quantitative detection of Borrelia burgdorferi sensu lato in erythema migrans skin lesions using internally controlled duplex real time PCR," PLoS ONE, vol. 8, no. 5, Article ID e63968, 2013.

[73] J. A. Branda, F. Strle, K. Strle, N. Sikand, M. J. Ferraro, and A. C. Steere, "Performance of United States serologic assays in the diagnosis of lyme borreliosis acquired in Europe," Clinical Infectious Diseases, vol. 57, no. 3, pp. 333-340, 2013.

[74] R. Iyer, P. Mukherjee, K. Wang, J. Simons, G. P. Wormser, and I. Schwartz, "Detection of Borrelia burgdorferi nucleic acids after antibiotic treatment does not confirm viability," Journal of Clinical Microbiology, vol. 51, no. 3, pp. 857-862, 2013.

[75] E. Sapi, N. Pabbati, A. Datar, E. M. Davies, A. Rattelle, and B. A. Kuo, "Improved culture conditions for the growth and detection of Borrelia from human serum," International Journal of Medical Sciences, vol. 10, no. 4, pp. 362-376, 2013.

[76] C. Nelson, S. Hojvat, B. Johnson et al., "Concerns regarding a new culture method for Borrelia burgdorferi not approved for the diagnosis of Lyme disease," Morbidity and Mortality Weekly Report, vol. 63, no. 15, p. 333, 2014.

[77] A. Wasiluk, N. Waszkiewicz, S. D. Szajda et al., "Alpha fucosidase and beta galactosidase in serum of a lyme disease patients as a possible marker of accelerated senescence--a preliminary study," Folia

Histochemica et Cytobiologica, vol. 50, no. 2, pp. 270-274, 2012.

[78] A. B. MacDonald, "Borrelia burgdorferi tissue morphologies and imaging methodologies," European Journal of Clinical Microbiology and Infectious Diseases, vol. 32, no. 8, pp. 10771082, 2013.

[79] S. T. Donta, R. B. Noto, and J. A. Vento, "SPECT brain imaging in chronic lyme disease," Clinical Nuclear Medicine, vol. 37, no. 9, pp. e219-e222, 2012.

[80] A. Z. Burakgazi, "Lyme disease--induced polyradiculopathy mimicking amyotrophic lateral sclerosis," International Journal of Neuroscience, vol. 124, no. 11, pp. 859-862, 2014.

[81] C. Ciuta, "Lyme disease--unusual medical encounter for an urologist," Revista medico-chirurgicala a Societajii de Medici [section]i Naturalisfi din Iasi, vol. 116, no. 4, pp. 1101-1105, 2012.

[82] S. J. Seligman, M. M. Petzke, and D. Bogunovic, "Pathogenesis of Post-Lyme Disease Symptoms," Clinical Infectious Diseases, vol. 59, no. 5, p. 747, 2014.

[83] A. M. Chandra, J. G. Keilp, and B. A. Fallon, "Correlates of perceived health-related quality of life in post-treatment Lyme encephalopathy," Psychosomatics, vol. 54, no. 6, pp. 552-559, 2013.

[84] D. Londono, D. Cadavid, E. E. Drouin et al., "Antibodies to endothelial cell growth factor and obliterative microvascular lesions in the synovium of patients with antibiotic-refractory lyme arthritis," Arthritis & Rheumatology, vol. 66, no. 8, pp. 2124-2133, 2014.

[85] G. Murillo, B. Ramirez, L. A. Romo, A. Munoz-Sanz, D. Hileeto, and M. Calonge, "Oculopalpebral borreliosis as an unusual manifestation of Lyme disease," Cornea, vol. 32, no. 1, pp. 8790, 2013.

[86] T. Chmielewski, J. Brydak-Godowska, B. Fieceket al., "Bacterial tick-borne diseases caused by Bartonella spp., Borrelia burgdorferi sensu lato, Coxiella burnetii, and Rickettsia spp. among patients with cataract surgery," Medical Science Monitor, vol. 20, pp. 927-931, 2014.

[87] M. Manek, A. Kulkarni, and A. Viera, "Hint of lyme, an uncommon cause of syncope," BMJ Case Reports, 2014.

[88] A. Maniu and L. Damian, "Rapid progressive bilateral hearing loss due to granulomatous otitis media in Lyme disease," The American Journal of Otolaryngology--Head and Neck Medicine and Surgery, vol. 34, no. 3, pp. 245-247, 2013.

[89] O. Yossepowitch, T. Gottesman, O. Schwartz-Harari, A. Soroksky, and M. Dan, "Aseptic meningitis and adult respiratory distress syndrome caused by Borrelia persica," Infection, vol. 40, no. 6, pp. 695-697, 2012.

[90] A. M. Noyes and J. Kluger, "A tale of two syndromes: Lyme disease preceding postural orthostatic tachycardia syndrome," Annals of Noninvasive Electrocardiology, 2014.

[91] G. Matera, A. Labate, A. Quirino et al., "Chronic neuroborreliosis by B. garinii: an unusual case presenting with epilepsy and multifocal brain MRI lesions," New Microbiologica, vol. 37, 393, no. 3, p. 397, 2014.

[92] J. Markeljevic, H. Sarac, and M. Rados, "Tremor, seizures and psychosis as presenting symptoms in a patient with chronic lyme neuroborreliosis (Lnb)," Collegium Antropologicum, vol. 35, supplement 1, pp. 313-318, 2011.

[93] N. A. Farshad-Amacker, H. Scheffel, T. Frauenfelder, and H. Alkadhi, "Brainstem abnormalities and vestibular nerve enhancement in acute Neuroborreliosis," BMC Research Notes, vol. 6, no. 1, article 551, 2013.

[94] R. Fathi, W. W. Huang, and K. Brown, "Disseminated Lyme borreliosis preceded by hepatitis in an African American male," Dermatology Online Journal, vol. 18, no. 10, article 4, 2012.

[95] G. Cassisi, P. Sarzi-Puttini, and M. Cazzola, "Chronic widespread pain and fibromyalgia: could there be some relationship with infections and vaccinations?" Clinical and Experimental Rheumatology, vol. 29, supplement 69, no. 6, pp. S118-S126, 2011.

[96] K. Iwata, T. Shimada, and H. Kawabata, "A case of lyme disease requiring over 1 year to diagnose at an infectious-disease clinic," Kansenshogaku zasshi, vol. 87, no. 1, pp. 44-48, 2013.

[97] S. E. Schutzer, T. E. Angel, T. Liu et al., "Distinct cerebrospinal fluid proteomes differentiate post-treatment Lyme disease from Chronic fatigue syndrome," PLoS ONE, vol. 6, no. 2, Article ID e17287, 2011.

[98] M. Kuhn, S. Grave, R. Bransfield, and S. Harris, "Long term antibiotic therapy may be an effective treatment for children co-morbid with Lyme disease and Autism Spectrum Disorder," Medical Hypotheses, vol. 78, no. 5, pp. 606-615, 2012.

[99] P. D. Glaude, A. M. Huber, T. Mailman, S. Ramsey, B. Lang, and E. Stringer, "A82: lyme arthritis: an emerging clinical problem in nova scotia, Canada," Arthritis & Rheumatology, vol. 66, supplement 3, p. S115, 2014.

[100] F. Blanc, N. Philippi, B. Cretin et al., "Lyme neuroborreliosis and dementia," Journal of Alzheimer's Disease, vol. 41, no. 4, pp. 10871093, 2014.

[101] N. S. Baranova, N. N. Spirin, L. A. Nizovtzeva, Y. A. Pakhomova, and O. A. Fadeeva, "Clinical and instrumental characteristics of chronic neuroborreliosis," Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova, vol. 112, no. 9, pp. 40-47, 2012.

[102] I. Erol, B. Klcarslan, S. Saygi, [section]. Demir, and F. Alehan, "Acute transverse myelitis in a child with lyme disease and a review of literature," Pediatric Neurology, vol. 48, no. 4, pp. 325-328,2013.

[103] R. Banerjee, J. J. Liu, and H. M. Minhas, "Lyme neuroborreliosis presenting with alexithymia and suicide attempts," The Journal of Clinical Psychiatry, vol. 74, no. 10, p. 981, 2013.

[104] L. E. Cottle, E. Mekonnen, M. B. J. Beadsworth, A. R. O. Miller, and N. J. Beeching, "Lyme disease in a British referral clinic," QJM, vol. 105, no. 6, pp. 537-543, 2012.

[105] W. Berghoff, "Chronic lyme disease and co-infections: differential diagnosis," The Open Neurology Journal, vol. 6, pp. 158-178, 2012.

[106] L. Michelet, S. Delannoy, E. Devillers et al., "High-throughput screening of tick-borne pathogens in Europe," Frontiers in Cellular and Infection Microbiology, vol. 4, p. 103, 2014.

[107] K. Chondrogiannis, A. Vezakis, M. Derpapas, A. Melemeni, and G. Fragulidis, "Seronegative cat-scratch disease diagnosed by PCR detection of Bartonella henselae DNA in lymph node samples," Brazilian Journal of Infectious Diseases, vol. 16, no. 1, pp. 96-99, 2012.

[108] M. H. Hersh, R. S. Ostfeld, D. J. McHenry et al., "Co-infection of blacklegged ticks with Babesia microti and Borrelia burgdorferi is higher than expected and acquired from small mammal hosts," PLoS ONE, vol. 9, no. 6, Article ID e99348, 2014.

[109] H. W. Horowitz, M. E. Aguero-Rosenfeld, D. Holmgren et al., "Lyme disease and human granulocytic anaplasmosis coinfection: impact of case definition on coinfection rates and illness severity," Clinical Infectious Diseases, vol. 56, no. 1, pp. 93-99, 2013.

[110] E. Tijsse-Klasen, H. Sprong, and N. Pandak, "Co-infection of Borrelia burgdorferi sensu lato and Rickettsia species in ticks and in an erythema migrans patient," Parasites & Vectors, vol. 6, article 347, 2013.

[111] P. J. Mayne, "Emerging incidence of Lyme borreliosis, babesiosis, bartonellosis, and granulocytic ehrlichiosis in Australia," International Journal of General Medicine, vol. 4, pp. 845-852, 2011.

[112] M. J. Middelveen, P. J. Mayne, D. G. Kahn, and R. B. Stricker, "Characterization and evolution of dermal filaments from patients with Morgellons disease," Clinical, Cosmetic and Investigational Dermatology, vol. 6, pp. 1-21, 2013.

[113] M. J. Middelveen, D. Burugu, A. Porur et al., "Association of spirochetal infection with Morgellons disease," F1000Research, vol. 2, p. 25, 2013.

[114] M. J. Middelveen and R. B. Stricker, "Filament formation associated with spirochetal infection: a comparative approach to Morgellons disease," Clinical, Cosmetic and Investigational Dermatology, vol. 4, pp. 167-177, 2011.

[115] J. Sperling, M. Middelveen, D. Klein, and F. Sperling, "Evolving perspectives on lyme borreliosis in Canada," The Open Neurology Journal, vol. 6, pp. 94-103, 2012.

[116] A. K. DeLong, B. Blossom, E. L. Maloney, and S. E. Phillips, "Antibiotic retreatment of Lyme disease in patients with persistent symptoms: a biostatistical review of randomized, placebo-controlled, clinical trials," Contemporary Clinical Trials, vol. 33, no. 6, pp. 1132-1142, 2012.

[117] R. B. Stricker and L. Johnson, "Lyme disease: the next decade," Infection and Drug Resistance, vol. 4, no. 1, pp. 1-9, 2011.

[118] R. B. Stricker, A. K. Delong, C. L. Green et al., "Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease," International Journal of General Medicine, vol. 4, pp. 639-646, 2011.

[119] E. Sapi, N. Kaur, S. Anyanwu et al., "Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi," Infection and Drug Resistance, vol. 4, no. 1, pp. 97-113, 2011.

[120] A. Amedei, G. Codolo, D. Ozolins et al., "Cerebrospinal fluid Tregulatory cells recognize Borrelia burgdorferi NapA in chronic lyme borreliosis," International Journal of Immunopathology and Pharmacology, vol. 26, no. 4, pp. 907-915, 2013.

[121] M. M. Safford, J. J. Allison, and C. I. Kiefe, "Patient complexity: more than comorbidity. The vector model of complexity," Journal of General Internal Medicine, vol. 22, no. 3, pp. 382-390, 2007

[122] F. Strle, G. P. Wormser, P. Mead et al., "Gender disparity between cutaneous and non-cutaneous manifestations of Lyme borreliosis," PLoS ONE, vol. 8, no. 5, Article ID e64110, 2013.

[123] J. D. Klein, S. C. Eppes, and P. Hunt, "Environmental and life-style risk factors for Lyme disease in children," Clinical Pediatrics, vol. 35, no. 7, pp. 359-363, 1996.

[124] J. Franke, A. Hildebrandt, and W. Dorn, "Exploring gaps in our knowledge on Lyme borreliosis spirochaetes--updates on complex heterogeneity, ecology, and pathogenicity," Ticks and Tick-borne Diseases, vol. 4, no. 1-2, pp. 11-25, 2013.

[125] X.-B. Ni, N. Jia, B.-G. Jiang et al., "Lyme borreliosis caused by diverse genospecies of Borrelia burgdorferi sensu lato in northeastern china," Clinical Microbiology and Infection, vol. 20, no. 8, pp. 808-814, 2014.

[126] E. Baranova, P. Solov Ev, E. Panfertsev et al., "Rational design of antigens to improve the serodiagnosis of tick-borne borreliosis in central regions of Russia," Advances in Experimental Medicine and Biology, vol. 807, pp. 9-21, 2014.

[127] S. P. Solomon, E. Hilton, B. S. Weinschel, S. Pollack, and E. Grolnick, "Psychological factors in the prediction of Lyme disease course," Arthritis Care & Research, vol. 11, no. 5, pp. 419-426, 1998.

[128] T. Kotter, F. A. Schaefer, M. Scherer, and E. Blozik, "Involving patients in quality indicator development--a systematic review," Patient Preference and Adherence, vol. 7, pp. 259-268, 2013.

[129] S. A. Chong, E. Abdin, C. Sherbourne et al., "Treatment gap in common mental disorders: the Singapore perspective," Epidemiology and Psychiatric Sciences, vol. 21, no. 2, pp. 195-202, 2012.

[130] A. Koski-Jannes, T. Hirschovits-Gerz, and M. Pennonen, "Population, professional, and client support for different models of managing addictive behaviors," Substance Use and Misuse, vol. 47, no. 3, pp. 296-308, 2012.

[131] L. Johnson, A. Aylward, and R. B. Stricker, "Healthcare access and burden of care for patients with Lyme disease: a large United States survey," Health Policy, vol. 102, no. 1, pp. 64-71, 2011.

[132] A. Vojdani, F. Hebroni, Y. Raphael, J. Erde, and B. Raxlen, "Novel diagnosis of lyme disease: potential for CAM intervention," Evidence-Based Complementary and Alternative Medicine, vol. 6, no. 3, pp. 283-295, 2009.

[133] M. Codony, J. Alonso, J. Almansa et al., "Perceived need for mental health care and service use among adults in Western Europe: results of the ESEMeD Project," Psychiatric Services, vol. 60, no. 8, pp. 1051-1058, 2009.

[134] S. Robinson, "Lyme Disease in Maine: a Comparison of NEDSS Surveillance Data and Maine Health Data Organization Hospital Discharge data," Online Journal of Public Health Informatics, vol. 5, no. 3, p. 231, 2014.

[135] H. Wilking and K. Stark, "Trends in surveillance data of human Lyme borreliosis from six federal states in eastern Germany, 2009-2012," Ticks and Tick-Borne Diseases, vol. 5, no. 3, pp. 219224, 2014.

[136] J. J. Halperin, P Baker, and G. P Wormser, "Common misconceptions about Lyme disease," The American Journal of Medicine, vol. 126, no. 3, pp. 264.e1-264.e7, 2013.

[137] P L. Solano, M. J. Mcduffie, H. B. Fagan, and K. Gifford, "Evaluation of educational interventions for three lesser-known illnesses," Delaware Medical Journal, vol. 85, no. 6, pp. 179-185, 2013.

[138] B. Henry, A. Crabtree, D. Roth, D. Blackman, and M. Morshed, "Lyme disease: knowledge, beliefs, and practices of physicians in a low-endemic area," Canadian Family Physician, vol. 58, no. 5, pp. e289-e295, 2012.

[139] A. Verbon, "The Health Council of the Netherlands' advice on Lyme disease," Nederlands Tijdschrift voor Geneeskunde, vol. 157, no. 29, Article ID A6626, 2013.

[140] R. Horowitz, Why Can't I Get Better? Solving the Mystery of Lyme and Chronic Disease, St. Martin's Press, New York, NY, USA, 1st edition, 2013.

[141] G. G. A. Pujalte and J. V. Chua, "Tick-borne infections in the United States," Primary Care: Clinics in Office Practice, vol. 40, no. 3, pp. 619-635, 2013.

[142] S. L. Valente, D. Wemple, S. Ramos, S. B. Cashman, and J. A. Savageau, "Preventive behaviors and knowledge of tick-borne illnesses: results of a survey from an endemic area," Journal of Public Health Management and Practice, 2014.

[143] J. M. Knoll, A. C. Ridgeway, C. M. Boogaerts, and G. A. Burket III, "Appalachian trail Hikers' ability to recognize Lyme disease by visual stimulus photographs," Wilderness & Environmental Medicine, vol. 25, no. 1, pp. 24-28, 2014.

Liesbeth Borgermans, (1) Geert Goderis, (2) Jan Vandevoorde, (1) and Dirk Devroey (1)

(1) Department of Family Medicine & Chronic Care, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103,1090 Brussels, Belgium

(2) Department of General Practice and University Hospitals Leuven, Katholieke Universiteit Leuven (KUL), Kapucijnenvoer 33, 3000 Leuven, Belgium

Correspondence should be addressed to Liesbeth Borgermans; liesbeth.borgermans@vub.ac.be

Received 11 July 2014; Accepted 12 November 2014; Published 24 November 2014

Academic Editor: Christos D. Lionis
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Borgermans, Liesbeth; Goderis, Geert; Vandevoorde, Jan; Devroey, Dirk
Publication:International Journal of Family Medicine
Article Type:Report
Geographic Code:4EUBL
Date:Jan 1, 2014
Words:8483
Previous Article:A change in students' perceptions of peer and faculty attitudes to rural medicine following the introduction of a rural health rotation.
Next Article:Comparing the effects of dietary flaxseed and omega-3 fatty acids supplement on cyclical mastalgia in Iranian women: a randomized clinical trial.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |